331A — Medix Income Statement
0.000.00%
- ¥4bn
- ¥680m
- ¥4bn
Annual income statement for Medix, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho |
| Standards: | JAS | JAS | JAS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 4,273 | 4,180 | 4,162 |
| Cost of Revenue | |||
| Gross Profit | 3,692 | 3,738 | 3,728 |
| Selling / General / Administrative Expenses | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 3,667 | 3,395 | 3,359 |
| Operating Profit | 606 | 785 | 803 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | 637 | 788 | 952 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 402 | 489 | 804 |
| Net Income Before Extraordinary Items | |||
| Net Income | 402 | 489 | 804 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 402 | 489 | 804 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 63.6 | 61.8 | 99.5 |
| Dividends per Share |